Type 3 diabetes
Type 3 diabetes is a proposed term for Alzheimer's disease resulting from insulin resistance (which is the primary problem associated with type 2 diabetes) and insulin deficiency (which the primary problem in type 1 diabetes).
A limited number of reviews have suggested mechanisms linking Alzheimer's and insulin resistance. Neurofibrillary tangles and hyper phosphorylated tau proteins in the brain are present in Alzheimer's disease. Glycogen synthase kinase 3β (GSK-3β) plays a role in the formation of the neurofibrillary tangles.
Multiple studies have been undertaken to determine the effects of insulin resistance and deficiency on the brain, research in this area is still being undertaken. There is some evidence to link people who have type 1 or 2 diabetes as having an increased risk of developing type 3 diabetes.
A deficiency or resistance to insulin can interact with proteins attributed to the development of Alzheimer’s disease. It is suggested that insulin deficiency or resistance can exacerbate the production of amyloid-beta protein and phosphorylation of tau protein which are implicated in the development of Alzheimer’s disease.
Evidence demonstrates that regular exercise can increase the body’s ability to effectively produce and use insulin in the body. Exercise has proven to prevent the development of both diabetes 1 and 2 as well as Alzheimer’s disease.
- "What is type 3 diabetes?". Diabetes NSW & ACT. 2019-08-30. Retrieved 2020-01-27.
- de la Monte, Suzanne M.; Wands, Jack R. (November 2008). "Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed". Journal of Diabetes Science and Technology. 2 (6): 1101–1113. doi:10.1177/193229680800200619. ISSN 1932-2968. PMC 2769828. PMID 19885299.
- "Type 3 Diabetes". diabetes.co.uk. Retrieved 2014-08-22.
- Owen Dyer (2005). "Is Alzheimer's really just type III diabetes?". National Review of Medicine. 2 (21). Archived from the original on 2015-02-14.
- Ahmed S, Mahmood Z, Zahid S (October 2015). "Linking insulin with Alzheimer's disease: emergence as type III diabetes". Neurol. Sci. 36 (10): 1763–9. doi:10.1007/s10072-015-2352-5. PMID 26248483.
- Kandimalla, Ramesk; Thirumala, Vani; Reddy, P. Hemachandra (May 2017). "Is Alzheimer's disease a Type 3 Diabetes? A Critical Appraisal". Biochimica et Biophysica Acta. 1863 (5): 1078–1089. doi:10.1016/j.bbadis.2016.08.018. ISSN 0006-3002. PMC 5344773. PMID 27567931.
- Moheet, Amir; Mangia, Silvia; Seaquist, Elizabeth R. (2015). "Impact of diabetes on cognitive function and brain structure". Annals of the New York Academy of Sciences. 1353 (1): 60–71. doi:10.1111/nyas.12807. ISSN 1749-6632. PMC 4837888. PMID 26132277.
- Femminella, Grazia Daniela; Bencivenga, Leonardo; Petraglia, Laura; Visaggi, Lucia; Gioia, Lucia; Grieco, Fabrizio Vincenzo; de Lucia, Claudio; Komici, Klara; Corbi, Graziamaria (2017). "Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives". Journal of Diabetes Research. doi:10.1155/2017/7420796. PMC 5471577. PMID 28656154. Retrieved 2020-01-27.
- Murphy, M. Paul; LeVine, Harry (2010-01-06). Lovell, Mark A. (ed.). "Alzheimer's Disease and the Amyloid-β Peptide". Journal of Alzheimer's Disease. 19 (1): 311–323. doi:10.3233/JAD-2010-1221. PMC 2813509. PMID 20061647.
- Editor (2019-01-15). "Type 3 diabetes is a title that has been proposed for Alzheimers disease which results from resistance to insulin in the brain". Diabetes. Retrieved 2020-01-27.CS1 maint: extra text: authors list (link)
- Li, Xiaohua; Song, Dalin; Leng, Sean X. (2015-03-10). "Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment". Clinical Interventions in Aging. doi:10.2147/cia.s74042. PMC 4360697. PMID 25792818. Retrieved 2020-01-27.
|This article about a medical condition affecting the nervous system is a stub. You can help Wikipedia by expanding it.|